Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Darren Chen: Overall, Patients Were Satisfied With Ophthalmic Video Visits
March 14th 2022A majority of patients with ophthalmic video visits were satisfied, but there were some predictors that contributed to which patients were more satisfied, explained Darren Chen, MD student at Weill Cornell Graduate School of Medical Sciences.
Read More
Dr Gregory Vidal: Some Populations Continue to Face Barriers to Care Despite Virtual Options
March 13th 2022Minority, low-income, and elderly patients faced greater barriers to care even when it went virtual during the pandemic, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
Read More
Patients With OAD and SMI Can Benefit From Integrated Personal Health and Social Care Interventions
March 10th 2022People who have both severe mental illness (SMI) and obstructive airways disease (OAD) experience extraordinary disability and isolation, which leads to a lack of access to care and increased use of urgent care.
Read More
Dr Gregory Vidal Highlights RPM Technologies for His Patients With Breast Cancer
March 6th 2022During the COVID-19 pandemic, there has been a lot of experimentation with new technologies for remote patient monitoring (RPM) to improve adherence and survival, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
Read More
Report: Economic Burden of Rare Diseases Is 10 Times Higher Than Mass Market Diseases
March 2nd 2022The economic burden of rare diseases based on direct, indirect, and mortality-related costs is 10 times greater than the burden for mass market diseases, such as diabetes and cardiovascular disease, and this burden increases when no treatment is available.
Read More
FDA Accepts sNDA for Zanubrutinib to Treat CLL/SLL
February 23rd 2022The supplemental new drug application (sNDA) filing includes data from 2 pivotal randomized phase 3 global studies, ALPINE and SEQUOIA, of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The target action date is October 22, 2022.
Read More
Xipere for Macular Edema Associated With Uveitis Launches in United States
February 16th 2022The treatment was approved in October 2021 and is the first FDA-approved therapy to treat macular edema associated with uveitis via injection to the suprachoroidal space, which provides a more targeted delivery mechanism.
Read More
Study Evaluates Impact of AE Severity on Health State Utility for CAR T Treatment in LBCL
February 9th 2022Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.
Read More
Presence of NAFLD Cirrhosis Impacts Best Response to Immunotherapy in Patients With HCC
January 29th 2022Disease progression was more likely to be the best response to immunotherapy for patients with hepatocellular carcinoma (HCC) and cirrhosis due to nonalcoholic fatty liver disease (NAFLD).
Read More
Incyte Withdraws FDA Submission for Parsaclisib for FL, MZL, MCL
January 27th 2022Incyte has become the latest company to pull an FDA filing following Gilead and Secura Bio, which both voluntarily withdrew therapies that had been granted accelerated approval but hadn’t completed confirmatory studies for full approval.
Read More